Compounds · Reproductive · Treatment of hypoactive sexual desire disorder
PT-141 (Bremelanotide / Vyleesi)
PT-141, Vyleesi, PT141
Also called Bremelanotide (Vyleesi), this melanocortin receptor agonist developed from Melanotan II gained FDA approval in 2019 for hypoactive sexual desire disorder in premenopausal women, only the second approved drug for that condition, and works through the brain rather than blood flow.
1.75 mg as needed (label dose)
Research score 90/100. Reference only, not a prescription.
- Libido Enhancement
- Hormone Regulation
- Melanocortin Agonist
- Mood Enhancement
- Erectile Function
- US status
- FDA Approved
- Approval
- FDA Approved
- Evidence
- FDA approved for Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Effective melanocortin receptor agonist.
- Research score
- 90 / 100
- Indication
- Female Sexual Dysfunction
- Origin
- USA
- Source category
- Reproductive System
- Status group
- Approved / prescription
Mechanism
Selectively activates MC4R in the central nervous system, engaging G-protein signaling that raises cAMP and PKA activity, altering neurotransmitter release in the hypothalamus and limbic system to boost sexual motivation via dopaminergic and adrenergic pathways.
Safety file
Nausea is very common, around 40%; flushing and headache occur; transient blood pressure rises can occur; frequent use risks permanent focal hyperpigmentation.
- Nausea
- Flushing
- Injection site reactions
- Headache
- Vomiting
- Temporary blood pressure elevation
Important: No more than one dose in 24 hours and no more than 8 doses a month. Do not use with uncontrolled high blood pressure or known heart disease: it raises blood pressure for a few hours after each dose.
Reconstitution
| Vial | 2 mL water | 3 mL water |
|---|---|---|
| 10 mg | 5 mg/mL | 3.33 mg/mL |
- Use bacteriostatic water as the diluent.
- Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
- Swirl gently to mix, then leave it to dissolve. Do not shake.
- Give it a few minutes. The finished solution should be clear and colourless.
Protocol
Route: Subcutaneous, on demand
Label protocol (subcutaneous, on demand)
- 1.75 mg, at least 45 minutes before activity, not on a daily schedule
- No more than one dose in 24 hours, and no more than 8 doses a month
- Stop if there is no benefit after 8 weeks
- At a 2 mL fill on a 10 mg vial (5 mg/mL), 1.75 mg is a 0.35 mL draw (35 units)
Use occasionally, do not stack
- This is an as-needed peptide, not a daily one
- Do not combine with Melanotan-2 or Melanotan-1; they act on the same melanocortin system
- Blood pressure rises briefly after each dose; avoid it with uncontrolled hypertension or heart disease
Dosing detail
- 1.75 mg, at least 45 minutes before activity. On demand, not daily: one dose per 24 hours at most, 8 per month at most.
- Nausea is the main side effect, along with facial flushing and headache.
- Works through the nervous system for libido rather than on blood flow like the ED drugs.
- Do not stack with MT-2 or MT-1 (same receptor family).
Duration
- Used occasionally, on demand, rather than in a continuous cycle.
Notes
- Also called bremelanotide (Vyleesi). Approved in the US for low sexual desire in premenopausal women.
- Nausea and facial flushing are the common effects.
- Inject subcutaneously into the abdomen or thigh.
Storage and handling
- Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
- Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
- Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
- If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.
NovaEvum vial
Worksheet
2 mL bacteriostatic water yields 5 mg/mL. The 1.75 mg label dose is 35 units.
- Catalog fill
- 10 mg
- Typical water
- 2 mL
- Route
- Subcutaneous
- Cycle
- No more than 8 doses a month. Stop after 8 weeks if there is no benefit.
| Step | Amount | Frequency | Notes |
|---|---|---|---|
| Label dose (Vyleesi) | 1.75 mg | As needed, max 1 per 24 h, 8 per month | 35 units from a 2 mL reconstitution |
- Nausea and flushing are common. Blood pressure rises for a few hours after each dose; do not use with uncontrolled hypertension or heart disease.
- This is not a substitute for medical evaluation of sexual or cardiovascular symptoms.
- Bacteriostatic water: 20–25 °C. Do not refrigerate the diluent.
- Amounts on this sheet are reconstitution math for the vial, not a recommendation.